A Phase 1/2 interventional study of Trastuzumab emtansine [Kadcyla] 3.0 mg/kg and Trastuzumab emtansine [Kadcyla] 3.6 mg/kg in Metastatic Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-24.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.
Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 35th largest by enrollment, is one of 6 that started in 2009, is one of 4 in phase 1/2, and was the 5th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
UNICANCER · Sites in France
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70 · Women only
University of Virginia · Sites in United States
Ages 18+
By country, each count listing its studies:
Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, Ado-Trastuzumab Emtansine is the treatment under test here. Read study by study →
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 32 · Phase 3 12 · Phase 4 1
First in 2006; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is close to the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 103 across the 56 interventional studies. Of the 36 that completed or were terminated, 24 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 56 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 124th largest by enrollment of the 170 interventional ones that give a count, is one of 18 that started in 2009, is one of 11 in phase 1/2, and was the 50th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06481956Zheng YabingT-DM1 Combined With CDK4/6 Inhibitor Ribociclib | 2027-01-10 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
| NCT07825753Fudan UniversityProtein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This was a multi-institutional, multinational, open-label, single-arm Phase Ib/II study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of trastuzumab emtansine (trastuzumab-MCC-DM1) administered by intravenous (IV) infusion in combination with pertuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced or metastatic breast cancer who had previously received trastuzumab.
There were 2 phases in the study, a Dose Escalation phase (Phase 1b) and a Dose Expansion phase (Phase 2a). In the Dose Escalation phase, 3 patients were enrolled at the first dose level (3.0 mg/kg trastuzumab emtansine) and and 6 patients were enrolled at the second dose level (3.6 mg/kg trastuzumab emtansine). An additional 58 patients were enrolled at the 3.6 mg/kg trastuzumab emtansine dose level in the Dose Expansion phase (Phase 2a) of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg · Drug: Pertuzumab 420 mg
Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg · Drug: Pertuzumab 420 mg
Drug page: Ado-Trastuzumab Emtansine
Trastuzumab emtansine was provided as a single-use lyophilized formulation.
Also known as: trastuzumab-DM1, trastuzumab-MCC-DM1, T-DM1
Drug page: Ado-Trastuzumab Emtansine
Trastuzumab emtansine was provided as a single-use lyophilized formulation.
Also known as: trastuzumab-DM1, trastuzumab-MCC-DM1, T-DM1
Pertuzumab was provided as a single-use formulation.
Also known as: Perjeta
Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
A patient had an objective response if they had a complete response or a partial response on 2 consecutive occasions ≥ 4 weeks apart. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.
Time frame: Baseline through the end of the study (up to 2 years 3 months)
Duration of Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Duration of objective response was defined as the time from initial response to disease progression (PD) or death from any cause. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.
Time frame: Baseline through the end of the study (up to 2 years 3 months)
Progression-free Survival Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Progression-free survival was defined as the time from randomization to first documented disease progression (PD) or death due to any cause within 30 days of the last treatment, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.
Time frame: Baseline through the end of the study (up to 2 years 3 months)
There were 2 phases in the study, a Dose Escalation phase (Phase 1b) and a Dose Expansion phase (Phase 2a).
| Milestone | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg |
|---|---|---|
| Started | 3 | 0 |
| Completed | 0 | 0 |
| Not completed | 3 | 0 |
| Withdrew: Disease progression | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Patient/legal guardian decision | 1 | 0 |
| Milestone | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg |
|---|---|---|
| Started | 0 | 6 |
| Completed | 0 | 0 |
| Not completed | 0 | 6 |
| Withdrew: Disease progression | 0 | 6 |
| Milestone | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg |
|---|---|---|
| Started | 0 | 58 |
| Completed | 0 | 11 |
| Not completed | 0 | 47 |
| Withdrew: Disease progression | 0 | 37 |
| Withdrew: Physician decision | 0 | 3 |
| Withdrew: Patient/legal guardian decision | 0 | 3 |
| Withdrew: Started non-protocol anti-cancer therapy | 0 | 3 |
| Withdrew: Death | 0 | 1 |
A patient had an objective response if they had a complete response or a partial response on 2 consecutive occasions ≥ 4 weeks apart. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.
| Percentage of patients | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg |
|---|---|---|
| Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) | 66.7 (13.5 to 98.3) | 40.6 (28.5 to 53.6) |
Duration of objective response was defined as the time from initial response to disease progression (PD) or death from any cause. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.
| Months | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg |
|---|---|---|
| Duration of Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) | 8.6 (NA to NA) | 13.9 (6.93 to NA) |
Progression-free survival was defined as the time from randomization to first documented disease progression (PD) or death due to any cause within 30 days of the last treatment, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.
| Months | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg |
|---|---|---|
| Progression-free Survival Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) | 13.8 (NA to NA) | 6.6 (4.21 to 9.46) |
Collected over From informed consent until treatment start (T), serious adverse events (SAE) related to protocol procedures were reported. From the start up to 30 days after the end of T, all AEs and SAEs were reported. Thereafter, only T-related SAEs were reported.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | — | 0/3 (0%) | 3/3 (100%) |
| Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg | — | 22/64 (34.4%) | 64/64 (100%) |
| Event | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg |
|---|---|---|
| CellulitisInfections and infestations | 0/3 | 3/64 |
| PneumoniaInfections and infestations | 0/3 | 3/64 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/3 | 3/64 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 3/64 |
| NauseaGastrointestinal disorders | 0/3 | 2/64 |
| VomitingGastrointestinal disorders | 0/3 | 2/64 |
| Abdominal painGastrointestinal disorders | 0/3 | 2/64 |
| Pericardial effusionCardiac disorders | 0/3 | 1/64 |
| TachycardiaCardiac disorders | 0/3 | 1/64 |
| ColitisGastrointestinal disorders | 0/3 | 1/64 |
| Event | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg |
|---|---|---|
| FatigueGeneral disorders | 3/3 | 39/64 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 7/64 |
| NauseaGastrointestinal disorders | 2/3 | 32/64 |
| ChillsGeneral disorders | 2/3 | 20/64 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 22/64 |
| DysgeusiaNervous system disorders | 2/3 | 16/64 |
| HeadacheNervous system disorders | 2/3 | 16/64 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/3 | 14/64 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/3 | 16/64 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 25/64 |
Treated population: All patients who received at least 1 dose of study drug and had at least 1 follow-up tumor assessment.
| Age, Continuous(years) | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg | Total |
|---|---|---|---|
| Mean | 53.3 ± 1.5 | 52.7 ± 10.8 | 52.7 ± 10.5 |
| Sex: Female, Male(Participants) | Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg | Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg | Total |
|---|---|---|---|
| Female | 3 | 63 | 66 |
| Male | 0 | 1 | 1 |
The record gives a start of May 2009, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ado-Trastuzumab Emtansine · Pertuzumab